Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Views On PFS Endpoint For Avastin Could Impact Fate Of Other First-Line Cancer Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Panel’s rejection of Genentech sBLA for first-line breast cancer despite meeting endpoint of progression-free survival leaves Wall Street wondering if same fate will befall ImClone/Bristol’s Erbitux in colon cancer.

You may also be interested in...



The Endgame on Oncology Endpoints

The annual ASCO meeting, held in Chicago this year, provided a forum for investigators to discuss the merits of continued use of progression-free survival as an endpoint in oncology clinical trials. Phase III data from Roche/Genentech's Avastin in metastatic breast cancer sparked debate.

Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases

CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.

Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases

CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel